As previously reported, TLR9, in combination with BCR as well as mutant isoforms of MYD88, could result in sustained activity of NF-κB in the activated B-cell-like subtype of diffuse large B-cell lymphoma [44]. Here, TLR9 is linked to diffuse large B-cell lymphoma.